References

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

10.1182/blood-2016-01-690636 · 2016 · External reference

The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms

10.1038/s41375-022-01613-1 · 2022 · External reference

The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee

10.1182/blood.2022015851 · 2022 · External reference

Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms

10.1111/his.15127 · 2024 · External reference

Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: a national registry study from England, 2013-2019

10.1111/bjh.18459 · 2022 · External reference

Recurrent BRAF mutations in Langerhans cell histiocytosis

10.1182/blood-2010-04-279083 · 2010 · External reference

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

10.1182/blood-2012-05-430140 · 2012 · External reference

Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms

10.1111/his.12416 · 2014 · External reference

Somatic activating ARAF mutations in Langerhans cell histiocytosis

10.1182/blood-2013-06-511139 · 2014 · External reference

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis

10.1182/blood-2014-05-577825 · 2014 · External reference

High prevalence of somatic MAP2K1 mutations in BRAF V600E negative Langerhans cell histiocytosis

10.1182/blood-2014-05-577361 · 2014 · External reference

MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis

10.1002/gcc.22247 · 2015 · External reference

Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis

10.1182/blood-2016-08-733790 · 2016 · External reference

New somatic BRAF splicing mutation in Langerhans cell histiocytosis

10.1186/s12943-017-0690-z · 2017 · External reference

Diverse and targetable kinase alterations drive histiocytic neoplasms

10.1158/2159-8290.cd-15-0913 · 2016 · External reference

Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

10.1038/s41591-019-0653-6 · 2019 · External reference

Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study

10.1182/bloodadvances.2022007947 · 2023 · External reference

Efficacy of MEK inhibition in patients with histiocytic neoplasms

10.1038/s41586-019-1012-y · 2019 · External reference

Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net

10.1186/1750-1172-8-72 · 2013 · External reference

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults

10.1182/blood.2021014343 · 2022 · External reference

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

10.1182/blood.2019003507 · 2020 · External reference

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

10.1182/blood-2018-03-839753 · 2018 · External reference

Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

10.1182/blood-2012-09-455774 · 2013 · External reference

The clinical spectrum of Erdheim-Chester disease: an observational cohort study

10.1182/bloodadvances.2016001784 · 2017 · External reference

Phenotypes and survival in Erdheim-Chester disease: results from a 165-patient cohort

10.1002/ajh.25055 · 2018 · External reference

Neurologic and oncologic features of Erdheim–Chester disease: a 30-patient series

10.1093/neuonc/noaa008 · 2020 · External reference

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease

10.3324/haematol.2019.219626 · 2020 · External reference

Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside

10.1002/pbc.22326 · 2010 · External reference

Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas

10.1002/pbc.26784 · 2018 · External reference

Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes

10.1182/blood-2017-10-812495 · 2018 · External reference

Malignant histiocytosis comprises a phenotypic spectrum that parallels the lineage differentiation of monocytes, macrophages, dendritic cells, and Langerhans cells

10.1016/j.modpat.2023.100268 · 2023 · External reference

Histiocytosis and the nervous system: from diagnosis to targeted therapies

10.1093/neuonc/noab107 · 2021 · External reference

Neurodegenerative central nervous system disease as late sequelae of Langerhans cell histiocytosis. report from the Japan LCH Study Group

10.3324/haematol.11827 · 2008 · External reference

Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study

10.1111/bjh.15577 · 2018 · External reference

The cognitive spectrum in neurodegenerative Langerhans cell histiocytosis

2014 · External reference

Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis

10.3174/ajnr.a0509 · 2007 · External reference

Neuropathology of CNS disease in Langerhans cell histiocytosis

10.1093/brain/awh403 · 2005 · External reference

Central nervous system disease in Langerhans cell histiocytosis

10.1016/j.jpeds.2010.03.001 · 2010 · External reference

CNS Langerhans cell histiocytosis: common hematopoietic origin for LCH-associated neurodegeneration and mass lesions

10.1002/cncr.31348 · 2018 · External reference

Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders

10.1016/j.immuni.2023.11.011 · 2023 · External reference

Targeted cancer therapy

10.1038/nature03095 · 2004 · External reference

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

10.1182/blood-2012-07-446286 · 2013 · External reference

Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis

10.1001/jamaoncol.2015.0736 · 2015 · External reference

Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations

10.1056/nejmoa1502309 · 2015 · External reference

Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF V600E -mutated Erdheim-Chester disease

10.1200/jco.2014.57.1950 · 2015 · External reference

Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH

10.1182/bloodadvances.2016003533 · 2017 · External reference

Vemurafenib for BRAF V600–mutant Erdheim-Chester disease and Langerhans cell histiocytosis

10.1001/jamaoncol.2017.5029 · 2018 · External reference

Mechanisms of resistance to RAF inhibitors in melanoma

10.1038/jid.2011.147 · 2011 · External reference

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis

10.3324/haematol.2017.185298 · 2018 · External reference

A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors

10.1158/1078-0432.ccr-17-3572 · 2019 · External reference

Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis

10.1182/bloodadvances.2022008414 · 2023 · External reference

Rosai–Dorfman disease with activating KRAS mutation — response to cobimetinib

10.1056/nejmc1713676 · 2017 · External reference

Trametinib in histiocytic sarcoma with an activating MAP2K1 (MEK1) mutation

10.1056/nejmc1511490 · 2018 · External reference

Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease

10.1111/bjh.14284 · 2018 · External reference

Outcomes after treatment with cobimetinib in patients with Rosai-Dorfman disease based on KRAS and MEK alteration status

10.1001/jamaoncol.2022.4432 · 2022 · External reference

Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis

10.1182/bloodadvances.2022009013 · 2023 · External reference

FDA approval summary: vemurafenib for the treatment of patients with Erdheim-Chester disease with the BRAFV600 mutation

10.1634/theoncologist.2018-0295 · 2018 · External reference

ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition

10.1182/blood.2021013338 · 2022 · External reference

Allele-specific mechanisms of activation of MEK1 mutants determine their properties

10.1158/2159-8290.cd-17-1452 · 2018 · External reference

Vulvar Langerhans cell histiocytosis: clinicopathologic characteristics, mutational profile, and treatment of 4 patients in a single-center cohort

10.1016/j.jdcr.2023.03.024 · 2023 · External reference

Childhood-onset Erdheim-Chester disease in the molecular era: clinical phenotypes and long-term outcomes of 21 patients

10.1182/blood.2023020569 · 2023 · External reference

International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology

10.1016/s0022-510x(96)00231-6 · 1997 · External reference

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)

10.1182/blood-2017-03-771873 · 2017 · External reference

Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study

10.1200/jco.19.00456 · 2019 · External reference

Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition

10.1182/blood-2018-10-878363 · 2019 · External reference

Effectiveness and safety of dabrafenib in the treatment of 20 Chinese children with BRAFV600E-mutated Langerhans cell histiocytosis

10.4143/crt.2020.769 · 2021 · External reference

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders

2024 · External reference

Pediatric histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16INK4A

10.1002/pbc.22810 · 2011 · External reference

PAX5 P80R-mutated B-cell acute lymphoblastic leukemia with transformation to histiocytic sarcoma: clonal evolution assessment using NGS-based immunoglobulin clonality and mutation analysis

10.1007/s00428-022-03428-y · 2023 · External reference

Transdifferentiation of B-lymphoblastic leukemia to histiocytic sarcoma after immunotherapy

10.1002/ajh.26983 · 2023 · External reference

Real-world toxicity experience with BRAF/MEK inhibitors in patients with Erdheim-Chester disease

10.1634/theoncologist.2019-0606 · 2020 · External reference

Low-dose vemurafenib monotherapy in BRAF V600E -mutated Erdheim-Chester disease

10.1080/10428194.2020.1783447 · 2020 · External reference

Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms

10.1111/bjh.18964 · 2023 · External reference

Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis

10.1182/bloodadvances.2021005442 · 2022 · External reference

Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH

10.1182/bloodadvances.2022009067 · 2023 · External reference

Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy

10.1093/noajnl/vdaa024 · 2020 · External reference

A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas

2017 · External reference

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

10.1038/s41591-023-02668-y · 2024 · External reference

Children with refractory histiocytosis treated by MAPKi have a high risk of neurodegeneration: an international study

2023 · External reference

Vemurafenib: the first drug approved for BRAF-mutant cancer

10.1038/nrd3847 · 2012 · External reference

Inhibition of mutated, activated BRAF in metastatic melanoma

10.1056/nejmoa1002011 · 2010 · External reference

Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAF V600E

10.1182/bloodadvances.2022007519 · 2022 · External reference

Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis

10.1182/bloodadvances.2021006732 · 2023 · External reference

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

10.1084/jem.20130977 · 2014 · External reference

Circulating cell-free BRAF V600E as a biomarker in children with Langerhans cell histiocytosis

10.1111/bjh.14695 · 2017 · External reference

Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults

10.1182/blood-2016-12-757823 · 2017 · External reference

Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis

10.1038/s41390-018-0238-y · 2019 · External reference

Bone marrow–derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis

10.1182/blood.2020005209 · 2020 · External reference

Circulating cell-free BRAF V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis

10.3324/haematol.2019.229187 · 2020 · External reference

A circulating subset of BRAF V600E -positive cells in infants with high-risk Langerhans cell histiocytosis treated with BRAF inhibitors

10.1111/bjh.17721 · 2021 · External reference

BRAF V600E mutation in cell-free DNA, rather than in lesion tissues, at diagnosis is an independent prognostic factor in children with Langerhans cell histiocytosis

10.1158/1535-7163.mct-20-1075 · 2021 · External reference

Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma

10.1111/bjh.18247 · 2022 · External reference

Response to mitogen-activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study

10.1111/bjh.17781 · 2022 · External reference